TP53 mutations determined by targeted NGS in breast cancer: a case-control study

CONCLUSIONS: Our case-control study suggests that TP53 somatic mutations detected by next-generation sequencing (NGS) are associated with an adverse prognosis in breast cancer.PMID:34676052 | PMC:PMC8522843 | DOI:10.18632/oncotarget.28071

Source: Oncotarget - October 22, 2021 Category: Cancer & Oncology Authors: Angeliki Andrikopoulou Evangelos Terpos Spyridoula Chatzinikolaou Kleoniki Apostolidou Ioannis Ntanasis-Stathopoulos Maria Gavriatopoulou Meletios-Athanasios Dimopoulos Flora Zagouri Source Type: research